IL105403A - Pharmaceutical preparation containing dichloromethylene bisphosphonic acid and process for its manufacture - Google Patents

Pharmaceutical preparation containing dichloromethylene bisphosphonic acid and process for its manufacture

Info

Publication number: IL105403A
Authority: IL; Israel
Prior art keywords: tablet; film; bisphosphonic acid; preparation according; dissolves
Prior art date: 1992-04-24

Application number

IL105403A

Other languages

English (en)

Other versions

IL105403A0 (en

Original Assignee

Leiras Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-24

Filing date

1993-04-15

Publication date

1998-03-10

1993-04-15 Application filed by Leiras Oy filed Critical Leiras Oy

1993-08-18 Publication of IL105403A0 publication Critical patent/IL105403A0/xx

1998-03-10 Publication of IL105403A publication Critical patent/IL105403A/en

Links

ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 title claims abstract description 27
238000000034 method Methods 0.000 title claims description 10
239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
238000004519 manufacturing process Methods 0.000 title claims description 4
239000013543 active substance Substances 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 8
239000003826 tablet Substances 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 14
238000012377 drug delivery Methods 0.000 claims description 7
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 5
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 4
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
229920002301 cellulose acetate Polymers 0.000 claims description 2
150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
239000008188 pellet Substances 0.000 claims description 2
229920002744 polyvinyl acetate phthalate Polymers 0.000 claims description 2
125000005591 trimellitate group Chemical group 0.000 claims description 2
230000000063 preceeding effect Effects 0.000 claims 2
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 claims 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
229960002286 clodronic acid Drugs 0.000 abstract description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
239000002253 acid Substances 0.000 description 4
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
239000002662 enteric coated tablet Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 3
229940075614 colloidal silicon dioxide Drugs 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
-1 Aqoat® by ShinEtsu) Chemical compound 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
JIUIIWVYHWSFAZ-UHFFFAOYSA-N ac1o0v2m Chemical compound O.O.O.O.O JIUIIWVYHWSFAZ-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
101150008563 spir gene Proteins 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL105403A 1992-04-24 1993-04-15 Pharmaceutical preparation containing dichloromethylene bisphosphonic acid and process for its manufacture IL105403A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9201299A SE501389C2 (sv)	1992-04-24	1992-04-24	Farmaceutiskt preparat och förfarande för dess framställning

Publications (2)

Publication Number	Publication Date
IL105403A0 IL105403A0 (en)	1993-08-18
IL105403A true IL105403A (en)	1998-03-10

Family

ID=20386054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL105403A IL105403A (en)	1992-04-24	1993-04-15	Pharmaceutical preparation containing dichloromethylene bisphosphonic acid and process for its manufacture

Country Status (21)

Country	Link
US (1)	US5525354A (fr)
EP (1)	EP0637236B1 (fr)
JP (1)	JP3536106B2 (fr)
AT (1)	ATE143802T1 (fr)
AU (1)	AU671830B2 (fr)
CA (1)	CA2134196C (fr)
CZ (1)	CZ282871B6 (fr)
DE (2)	DE69305335T2 (fr)
DK (1)	DK0637236T3 (fr)
EE (1)	EE03107B1 (fr)
ES (1)	ES2094539T3 (fr)
FI (1)	FI110667B (fr)
GR (1)	GR3022249T3 (fr)
HK (1)	HK13097A (fr)
HU (1)	HU219342B (fr)
IL (1)	IL105403A (fr)
NO (1)	NO306654B1 (fr)
RU (1)	RU2116074C1 (fr)
SE (1)	SE501389C2 (fr)
TW (1)	TW273515B (fr)
WO (1)	WO1993021907A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6406714B1 (en)	1992-12-02	2002-06-18	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids
BR9307859A (pt) †	1993-05-15	1996-01-09	Boehringer Mannheim Gmbh	Comprimido com biodisponibilidade aperfeiçoada que contérn ácido
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
FI94926C (fi) *	1993-11-12	1995-11-27	Leiras Oy	Menetelmä klodronaattivalmisteen valmistamiseksi
US20010007863A1 (en)	1998-06-18	2001-07-12	Merck & Co., Inc.	Wet granulation formulation for bisphosphonic acids
TW390813B (en) *	1994-04-29	2000-05-21	Merck & Co Inc	Wet granulation formulation for bisphosphonic acids
FI98343C (fi) *	1995-03-21	1997-06-10	Orion Yhtymae Oy	Peroraalinen formulaatio
DE19719680A1 (de)	1997-05-09	1998-11-19	Boehringer Mannheim Gmbh	Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
JPH11137208A (ja) *	1997-11-14	1999-05-25	Nikken Chem Co Ltd	口腔内速溶性固形物及びその製造方法
EP0998933A1 (fr) *	1998-10-09	2000-05-10	Boehringer Mannheim Gmbh	Procédé pour la préparation de compositions pharmaucetiques contenant des diphosphonates pour administration orale
EP0998932A1 (fr) *	1998-10-09	2000-05-10	Boehringer Mannheim Gmbh	Forme d'administration pharmaceutique contenant des diphosphonates ou leurs sels et méthode pour la fabriquer
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
CA2363123C (fr) *	1999-02-22	2011-09-06	Kenneth Iain Cumming	Dose orale solide contenant un agent de potentialisation
SE9901272D0 (sv) *	1999-04-09	1999-04-09	Astra Ab	New improved formulation
US6410520B2 (en)	2000-02-01	2002-06-25	The Procter & Gamble Company	Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6562974B2 (en)	2000-02-01	2003-05-13	The Procter & Gamble Company	Process for making geminal bisphosphonates
NZ527157A (en) *	2001-03-01	2005-04-29	Emisphere Tech Inc	Compositions for delivering bisphosphonates
EP1390383B1 (fr)	2001-05-11	2012-02-29	Isis Pharmaceuticals, Inc.	Renforcateurs de permeation antisens
US20030070584A1 (en) *	2001-05-15	2003-04-17	Cynthia Gulian	Dip coating compositions containing cellulose ethers
AU4061702A (en) *	2001-05-15	2003-04-03	Mcneil-Ppc, Inc.	Dip coating compositions containing starch or dextrin
US8309118B2 (en) *	2001-09-28	2012-11-13	Mcneil-Ppc, Inc.	Film forming compositions containing sucralose
US7429619B2 (en) *	2002-08-02	2008-09-30	Mcneil Consumer Healthcare	Polyacrylic film forming compositions
US20080287400A1 (en)	2004-05-24	2008-11-20	Richard John Dansereau	Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en)	2004-05-24	2010-01-12	The Procter & Gamble Company	Dosage forms of risedronate
US7645459B2 (en)	2004-05-24	2010-01-12	The Procter & Gamble Company	Dosage forms of bisphosphonates
US20080286359A1 (en)	2004-05-24	2008-11-20	Richard John Dansereau	Low Dosage Forms Of Risedronate Or Its Salts
US7862552B2 (en) *	2005-05-09	2011-01-04	Boston Scientific Scimed, Inc.	Medical devices for treating urological and uterine conditions
WO2007117706A2 (fr)	2006-04-07	2007-10-18	Merrion Research Iii Limited	Forme pharmaceutique solide par voie orale contenant un activateur
DE102008022520A1 (de) *	2008-05-07	2009-11-12	Bayer Animal Health Gmbh	Feste Arzneimittelformulierung mit verzögerter Freisetzung
CN102046192B (zh)	2008-05-07	2014-11-19	默里昂研究Ⅲ有限公司	GnRH相关化合物的组合物及制备方法
WO2011120033A1 (fr)	2010-03-26	2011-09-29	Merrion Research Iii Limited	Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
WO2012094598A2 (fr)	2011-01-07	2012-07-12	Merrion Research Iii Limited	Compositions pharmaceutiques de fer pour administration orale
US10265384B2 (en)	2015-01-29	2019-04-23	Novo Nordisk A/S	Tablets comprising GLP-1 agonist and enteric coating

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57171428A (en) *	1981-04-13	1982-10-22	Sankyo Co Ltd	Preparation of coated solid preparation
DE3767998D1 (de) *	1986-12-20	1991-03-14	Boehringer Mannheim Gmbh	Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
EP0313845A1 (fr) *	1987-09-29	1989-05-03	Warner-Lambert Company	Stabilisation d'une forme pharmaceutique entérique enrobée
FR2629716B1 (fr) *	1988-04-07	1991-07-19	Sanofi Sa	Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique

1992
- 1992-04-24 SE SE9201299A patent/SE501389C2/sv not_active IP Right Cessation
1993
- 1993-04-13 TW TW082102782A patent/TW273515B/zh active
- 1993-04-15 IL IL105403A patent/IL105403A/en not_active IP Right Cessation
- 1993-04-21 DE DE69305335T patent/DE69305335T2/de not_active Expired - Fee Related
- 1993-04-21 US US08/318,650 patent/US5525354A/en not_active Expired - Lifetime
- 1993-04-21 AU AU39550/93A patent/AU671830B2/en not_active Ceased
- 1993-04-21 RU RU94045950A patent/RU2116074C1/ru not_active IP Right Cessation
- 1993-04-21 CZ CZ942614A patent/CZ282871B6/cs not_active IP Right Cessation
- 1993-04-21 AT AT93908973T patent/ATE143802T1/de not_active IP Right Cessation
- 1993-04-21 JP JP51895893A patent/JP3536106B2/ja not_active Expired - Fee Related
- 1993-04-21 ES ES93908973T patent/ES2094539T3/es not_active Expired - Lifetime
- 1993-04-21 CA CA002134196A patent/CA2134196C/fr not_active Expired - Fee Related
- 1993-04-21 EP EP93908973A patent/EP0637236B1/fr not_active Expired - Lifetime
- 1993-04-21 HU HU9403067A patent/HU219342B/hu not_active IP Right Cessation
- 1993-04-21 DK DK93908973.6T patent/DK0637236T3/da active
- 1993-04-21 DE DE0637236T patent/DE637236T1/de active Pending
- 1993-04-21 WO PCT/FI1993/000166 patent/WO1993021907A1/fr not_active Ceased
1994
- 1994-10-21 FI FI944961A patent/FI110667B/fi active
- 1994-10-21 NO NO944001A patent/NO306654B1/no unknown
- 1994-11-15 EE EE9400134A patent/EE03107B1/xx not_active IP Right Cessation
1997
- 1997-01-09 GR GR970400013T patent/GR3022249T3/el unknown
- 1997-02-05 HK HK13097A patent/HK13097A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ261494A3 (en)	1995-02-15
RU94045950A (ru)	1996-11-10
ES2094539T3 (es)	1997-01-16
GR3022249T3 (en)	1997-04-30
HU219342B (en)	2001-03-28
RU2116074C1 (ru)	1998-07-27
NO306654B1 (no)	1999-12-06
JPH07505898A (ja)	1995-06-29
NO944001L (no)	1994-10-21
IL105403A0 (en)	1993-08-18
DE637236T1 (de)	1995-07-06
AU3955093A (en)	1993-11-29
CZ282871B6 (cs)	1997-11-12
HK13097A (en)	1997-02-14
US5525354A (en)	1996-06-11
WO1993021907A1 (fr)	1993-11-11
FI944961L (fi)	1994-10-21
EP0637236A1 (fr)	1995-02-08
FI944961A0 (fi)	1994-10-21
DE69305335T2 (de)	1997-04-30
DE69305335D1 (de)	1996-11-14
DK0637236T3 (da)	1997-03-17
AU671830B2 (en)	1996-09-12
SE9201299D0 (sv)	1992-04-24
HU9403067D0 (en)	1994-12-28
TW273515B (fr)	1996-04-01
CA2134196A1 (fr)	1993-11-11
EP0637236B1 (fr)	1996-10-09
CA2134196C (fr)	2004-02-10
JP3536106B2 (ja)	2004-06-07
SE9201299L (sv)	1993-10-25
FI110667B (fi)	2003-03-14
NO944001D0 (no)	1994-10-21
EE03107B1 (et)	1998-08-17
ATE143802T1 (de)	1996-10-15
HUT74572A (en)	1997-01-28
SE501389C2 (sv)	1995-01-30

Legal Events

Date	Code	Title
1998-09-24	FF	Patent granted
1999-01-26	KB	Patent renewed
1999-10-28	KB	Patent renewed
2003-07-06	KB	Patent renewed
2007-07-24	KB	Patent renewed
2011-12-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5525354A (en)	1996-06-11	Pharmaceutical preparation and process for its manufacture
US6010718A (en)	2000-01-04	Extended release formulations of erythromycin derivatives
US5520931A (en)	1996-05-28	Controlled release morphine preparation
US4673564A (en)	1987-06-16	Sustained release pharmaceutical composition of solid medical material
EP0255404B1 (fr)	1991-01-23	Préparation d'ibuprofen à libération prolongée
US5811126A (en)	1998-09-22	Controlled release matrix for pharmaceuticals
US4753801A (en)	1988-06-28	Sustained release tablets
KR100348585B1 (ko)	2002-10-31	다리페나신을함유하는약학제제
JPH11171775A (ja)	1999-06-29	テオフィリン徐放性錠剤
HU196708B (en)	1989-01-30	Process for producing pharmaceutical composition comprising omeprazol and suitable for treating deseases of the digestive system
NZ201008A (en)	1985-11-08	Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
JPH03190817A (ja)	1991-08-20	徐放性調剤単位
US20060159758A1 (en)	2006-07-20	Coating composition for taste masking coating and methods for their application and use
WO1998026767A2 (fr)	1998-06-25	Formulations a liberation lente et specifique d'un site, pour l'administration de mesalazine
WO2008083561A1 (fr)	2008-07-17	Composition pharmaceutique orale de glycyrrhizine ou ses sels et son procédé de préparation
MXPA05004648A (es)	2005-06-08	Comprimidos orales de liberacion extendida y procedimientos de preparacion y uso de los mismos.
IE57220B1 (en)	1992-06-03	Ph independent controlled releasable tablets
JP6328138B2 (ja)	2018-05-23	Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
EP1560568A1 (fr)	2005-08-10	Compositions pharmaceutiques a liberation controlee contenant de l'alginate de sodium et de l'alginate de sodium et calcium.
CN115804774A (zh)	2023-03-17	一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
HK1027023B (en)	2004-10-15	Extended release formulations of clarithromycin
CA2632039A1 (fr)	2007-06-28	Granules a rupture